Hans-Christoph Diener, Gerrit M Grosse, Anika Hüsing, Andreas Stang, Nils Kuklik, Marcus Brinkmann, Gabriele D Maurer, Hassan Soda, Carsten Pohlmann, Rüdiger Hilker-Roggendorf, Nikola Popovic, Peter Kraft, Bruno-Marcel Mackert, Christoph C Eschenfelder, Christian Weimar
INTRODUCTION: Factor Xa (FXa) inhibitors are superior to vitamin K antagonists (VKAs) in terms of avoiding hemorrhagic complications. However, no robust data are available to date as to whether this also applies to the early phase after stroke. In this prospective registry study, we aimed to investigate whether anticoagulation with FXa inhibitors in the early phase after acute ischemic stroke or transient ischemic attack (TIA) is associated with a lower risk of major bleeding events compared with VKAs...
April 3, 2024: European Stroke Journal